Estonya - Estonca - Ravimiamet

krka, d.d., novo mesto - agomelatiin - õhukese polümeerikattega tablett - 25mg 30tk; 25mg 56tk; 25mg 98tk; 25mg 28tk

Estonya - Estonca - Ravimiamet

zentiva k.s. - agomelatiin - õhukese polümeerikattega tablett - 25mg 84tk

Estonya - Estonca - Ravimiamet

sandoz gmbh - tsefuroksiim - kaetud tablett - 500mg 10tk; 500mg 24tk; 500mg 8tk; 500mg 12tk

Estonya - Estonca - Ravimiamet

sandoz pharmaceuticals d.d. - piperatsilliin+tasobaktaam - süste-/infusioonilahuse pulber - 4000mg+500mg 5tk; 4000mg+500mg 1tk; 4000mg+500mg 50tk; 4000mg+500mg 10tk

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - ravimid hingamisteede obstruktiivsete haiguste, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastilised ained - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

Estonya - Estonca - Ravimiamet

first pharma oÜ - esetimiib - tablett - 10mg 56tk; 10mg 30tk; 10mg 100tk; 10mg 98tk; 10mg 50tk; 10mg 14tk; 10mg 60tk; 10mg 90tk

Estonya - Estonca - Ravimiamet

mcneil healthcare (ireland) limited - tetrüsoliin - silmatilgad, lahus - 0,5mg 1ml 15ml 1tk

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

janssen-cilag international nv - rilpivirine - hiv-nakkused - viirusevastased ravimid süsteemseks kasutamiseks - rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (hiv 1) infection in adults who are virologically suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the nnrti and ini class.

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - rinnanäärmed - antineoplastilised ained - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.